Methamphetamine Dependence
Conditions
Keywords
Methamphetamine, Dependency, Addiction, vigabatrin
Brief summary
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be methamphetamine-free in the last 2 weeks of the study's Treatment Phase (Weeks 11 and 12).
Detailed description
This is a Phase II, randomized, double-blind, placebo-controlled, intent-to-treat, 2-arm, parallel design, multicenter study to evaluate vigabatrin as a treatment for methamphetamine addiction. The study will involve approximately 180 subjects (90/group) who meet DSM IV criteria for methamphetamine dependence. Subjects will be evaluated for their compliance with protocol inclusion/exclusion criteria during Screening/Baseline Phase, lasting up to 4 weeks. At the conclusion of the Screening/Baseline Phase, subjects meeting all inclusion/exclusion criteria will be randomized to one of two treatment groups: vigabatrin or placebo. Subjects will proceed to a 12 week Treatment Phase and then undergo a 12 week follow-up period. Subjects will be scheduled for clinic visits 3 times per week for efficacy and/or safety assessments during the Screening/Baseline Phase and the 12 week Treatment Phase. Subjects will return for follow up visits at Weeks 13, 16, 20 and 24.
Interventions
DRUGCPP-109 vigabatrin
tablets, bid for 12 weeks
DRUGMatching Placebo
tablets, bid, 12 weeks
Sponsors
Catalyst Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Able to understand the study and provide written informed consent. * Male or female at least 18 years of age. * Meets DSM-IV (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) criteria for methamphetamine dependence as major diagnosis, as determined by the Substance Abuse module of SCID (Structured Clinical Interview for DSM-IV). * Provides at least one urine specimen which is positive for methamphetamine according to a rapid screening test. * Seeking treatment for methamphetamine dependence. * Have normal visual fields. * Be in generally good health based on history, physical examination and laboratory findings. * If female of childbearing potential, use acceptable contraceptive methods
Exclusion criteria
* Has current dependence on any psychoactive substance other than methamphetamine, alcohol, nicotine, or cannabinoid or physiologic dependence on alcohol requiring medical detoxification. * Has any serious medical or psychiatric illness and/or clinically significant abnormal laboratory values. * Has history of serious cardiovascular reaction to methamphetamine. * Has clinically significant cardiovascular impairment, abnormal ECG or uncontrolled hypertension. * Be under court or other governmental agency (e.g. social services) mandate to obtain treatment or requiring outside urine monitoring. * Be enrolled in an opiate substitution treatment program within 2 months of randomization. * Has ever taken vigabatrin in the past. * Is pregnant or lactating. * Has clinically significant ophthalmologic disease, which would preclude safety monitoring, is undergoing treatment for ocular disease or intends to have any ocular surgery or procedure performed during the time of their participation in the trial. * Has received a drug with known major organ toxicity, including retinotoxicity. * Is currently participating in, or has been enrolled in another clinical trial within the last 30 days. * Be anyone who, in the judgment of the investigator, would not be expected to attend regular study visits or to complete the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Proportion of Subjects in Each Treatment Group Who Are Amphetamine Abstinent During the Last 2 Weeks of the Treatment Phase (Weeks 11 and 12). | Weeks 11-12 |
Secondary
| Measure | Time frame |
|---|---|
| • Number of Methamphetamine Negative Urines During the Treatment Phase • Number of Methamphetamine Use Weeks During the Treatment Phase. | Weeks 1-12 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Vigabatrin CPP-109 vigabatrin tablets
CPP-109 vigabatrin: tablets, bid for 12 weeks | 28 |
| Matching Placebo Matching Placebo Tablets
Matching Placebo: tablets, bid, 12 weeks | 27 |
| Total | 55 |
Baseline characteristics
| Characteristic | Vigabatrin | Matching Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 28 Participants | 27 Participants | 55 Participants |
| Age, Continuous | 44 years | 42 years | 43 years |
| Methamphetamine substance dependence | 28 Participants | 27 Participants | 55 Participants |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment United States | 28 participants | 27 participants | 55 participants |
| Sex: Female, Male Female | 19 Participants | 18 Participants | 37 Participants |
| Sex: Female, Male Male | 9 Participants | 9 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 28 | 0 / 27 |
| other Total, other adverse events | 24 / 28 | 23 / 27 |
| serious Total, serious adverse events | 2 / 28 | 0 / 27 |
Outcome results
Primary
The Proportion of Subjects in Each Treatment Group Who Are Amphetamine Abstinent During the Last 2 Weeks of the Treatment Phase (Weeks 11 and 12).
Time frame: Weeks 11-12
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Vigabatrin | The Proportion of Subjects in Each Treatment Group Who Are Amphetamine Abstinent During the Last 2 Weeks of the Treatment Phase (Weeks 11 and 12). | 4 Participants |
| Placebo | The Proportion of Subjects in Each Treatment Group Who Are Amphetamine Abstinent During the Last 2 Weeks of the Treatment Phase (Weeks 11 and 12). | 2 Participants |
Secondary
• Number of Methamphetamine Negative Urines During the Treatment Phase • Number of Methamphetamine Use Weeks During the Treatment Phase.
Time frame: Weeks 1-12
Population: Data were not collected due to early study termination.